Skip to main navigation Skip to search Skip to main content

Surface CD52, CD84, and PTGER2 mark mature PMN-MDSCs from cancer patients and G-CSF-treated donors

  • Francesca Pettinella
  • , Barbara Mariotti
  • , Chiara Lattanzi
  • , Kirsten Bruderek
  • , Marta Donini
  • , Sara Costa
  • , Olivia Marini
  • , Giulia Iannoto
  • , Sara Gasperini
  • , Elena Caveggion
  • , Monica Castellucci
  • , Federica Calzetti
  • , Francisco Bianchetto-Aguilera
  • , Elisa Gardiman
  • , Matteo Giani
  • , Stefano Dusi
  • , Maurizio Cantini
  • , Aurora Vassanelli
  • , Denise Pavone
  • , Michele Milella
  • Sara Pilotto, Pamela Biondani, Benedikt Höing, Marie Carolin Schleupner, Timon Hussain, Boris Hadaschik, Cordelia Kaspar, Carlo Visco, Cristina Tecchio, Leo Koenderman, Flavia Bazzoni, Nicola Tamassia, Sven Brandau, Marco A. Cassatella*, Patrizia Scapini*
*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

5 Downloads (Pure)

Abstract

Precise molecular characterization of circulating polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) is hampered by their mixed composition of mature and immature cells and lack of specific markers. Here, we focus on mature CD66b+CD10+CD16+CD11b+ PMN-MDSCs (mPMN-MDSCs) from either cancer patients or healthy donors receiving G-CSF for stem cell mobilization (GDs). By RNA sequencing (RNA-seq) experiments, we report the identification of a distinct gene signature shared by the different mPMN-MDSC populations under investigation, also validated in mPMN-MDSCs from GDs and tumor-associated neutrophils (TANs) by single-cell RNA-seq (scRNA-seq) experiments. Analysis of such a gene signature uncovers a specific transcriptional program associated with mPMN-MDSC differentiation and allows us to identify that, in patients with either solid or hematologic tumors and in GDs, CD52, CD84, and prostaglandin E receptor 2 (PTGER2) represent potential mPMN-MDSC-associated markers. Altogether, our findings indicate that mature PMN-MDSCs distinctively undergo specific reprogramming during differentiation and lay the groundwork for selective immunomonitoring, and eventually targeting, of mature PMN-MDSCs.

Original languageEnglish
Article number101380
JournalCell reports medicine
Volume5
Issue number2
DOIs
Publication statusPublished - 20 Feb 2024

Keywords

  • biomarkers
  • cancer patients
  • G-CSF
  • neutrophils
  • PMN-MDSCs

Fingerprint

Dive into the research topics of 'Surface CD52, CD84, and PTGER2 mark mature PMN-MDSCs from cancer patients and G-CSF-treated donors'. Together they form a unique fingerprint.

Cite this